Drug Resistance in Difficult-to-Treat Rheumatoid Arthritis: Why Treatments Stop Working and What Could Help

Rheumatoid arthritis (RA) is a long-term autoimmune condition in which the immune system mistakenly attacks the tissues lining the joints. This can lead to pain, swelling, stiffness and, if inflammation remains uncontrolled, progressive joint damage.

Disease-modifying antirheumatic drugs (DMARDs) help control the underlying disease process and reduce the risk of long-term complications.

However, not everyone responds adequately to treatment. Some people continue to experience active disease despite trying several medicines, while others initially improve but later lose their response. These challenges are part of what makes difficult-to-treat rheumatoid arthritis an important area of research.

A review published in Biochemical Pharmacology in 2026 examines how changes in drug transport, cellular metabolism, immune responses and inflammatory signalling may contribute to treatment resistance.

It also discusses emerging approaches that could eventually help clinicians manage patients whose disease remains difficult to control.()

Difficult-to-treat rheumatoid arthritis (D2T-RA) describes a complex situation in which disease activity or treatment-related challenges persist despite the use of multiple therapies. The European Alliance of Associations for Rheumatology (EULAR) has developed a framework to help identify this group of patients.

The review cited in the 2026 report estimates that D2T-RA affects approximately 6% to 21% of people with rheumatoid arthritis. The range reflects differences in patient populations, definitions and study methods.

Importantly, persistent joint pain does not always mean that the disease is still actively inflamed. Symptoms may also be influenced by existing joint damage, osteoarthritis, fibromyalgia, fatigue, mental health conditions or other health problems. Treatment adherence and medication tolerability can also affect outcomes.

This distinction matters because changing or escalating immunosuppressive treatment may not help when symptoms are being driven by something other than active rheumatoid inflammation. A careful clinical assessment is therefore an important part of managing suspected treatment resistance.()

Methotrexate is a commonly used conventional synthetic DMARD and remains an important treatment for rheumatoid arthritis. It helps reduce immune-driven inflammation and may be prescribed alone or alongside other medicines.

However, the 2026 review reports that approximately 30% to 50% of clinical cases may show inadequate response to methotrexate. This does not necessarily mean that the medicine has become ineffective in every patient. Inadequate response can have several explanations, including differences in disease biology, treatment exposure and individual drug handling.

Researchers have identified several possible cellular mechanisms.

For a medicine to work inside a cell, it must reach the appropriate location and remain there at an effective concentration. Certain transport proteins help medicines enter cells, while others move substances out.

The review discusses reduced activity of transport systems involved in methotrexate uptake, including organic anion transporter 3 and reduced folate carriers. If less medicine enters the cell, its therapeutic effect may be limited.

At the same time, ATP-binding cassette (ABC) transporters can move drugs out of cells. Two proteins highlighted in the review are P-glycoprotein and breast cancer resistance protein (BCRP). Increased drug efflux may reduce the amount of methotrexate retained inside relevant cells.

The review also describes metabolic changes that may support drug resistance. Some inflammatory cells shift towards increased glycolysis, a process through which cells break down glucose to generate energy.

Hypoxia-inducible factor (HIF) signalling may contribute to this metabolic adaptation. Researchers are investigating whether these changes provide the energy needed to sustain drug-efflux activity and help inflammatory cells survive despite treatment.

Epigenetics refers to changes in how genes are switched on or off without altering the underlying DNA sequence. DNA methylation and non-coding RNA molecules can influence cell behaviour.

In rheumatoid arthritis, fibroblast-like synoviocytes are cells found in the joint lining. When these cells acquire aggressive, inflammation-supporting characteristics, they may contribute to persistent tissue inflammation and joint damage.

The review discusses how altered DNA methylation and non-coding RNA profiles may help maintain these abnormal cellular behaviours, including resistance to normal cell-death signals. These mechanisms are research findings rather than routine clinical tests for deciding whether methotrexate will work.()

Biologic DMARDs target specific components of the immune system that contribute to rheumatoid arthritis. Depending on the medicine, they may block tumour necrosis factor (TNF), interleukin-6 (IL-6) signalling or other immune pathways.

Some patients initially respond well but later experience a reduction in treatment effectiveness. One possible explanation is the development of anti-drug antibodies.

Anti-drug antibodies are immune proteins produced by the body that recognise a therapeutic biologic as a target. They may interfere with the medicine's ability to bind to its intended target or increase how quickly the drug is cleared from the body.

The likelihood of an immune response can vary according to the structure of the biologic medicine and individual patient characteristics. The review discusses differences between chimeric and fully human antibody-based treatments, as well as the possible influence of human leukocyte antigen (HLA) variations.

Some biologics are more likely than others to trigger clinically relevant immune responses. However, the development of antibodies does not automatically mean that treatment has failed; their clinical significance depends on factors such as antibody levels, drug concentration and the patient's disease activity.

Methotrexate is sometimes prescribed alongside biologic medicines. In certain treatment combinations, it may reduce the likelihood of developing anti-drug antibodies and help maintain therapeutic effectiveness.

The review discusses possible immune-regulatory explanations for this effect. However, the decision to combine medicines depends on the specific biologic, the patient's medical history, treatment response and safety considerations.()

Rheumatoid arthritis is driven by a network of immune signals rather than a single inflammatory molecule. This means that blocking one pathway may not always be enough to control the disease.

For example, a treatment that targets TNF may reduce inflammation through that pathway, but other signalling systems can continue to contribute to disease activity. The 2026 review highlights interleukin-6, interleukin-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) as pathways being investigated in the context of persistent inflammation.

This concept is sometimes described as pathway bypass. In simple terms, inflammation may continue through alternative biological routes even when one therapeutic target has been blocked.

It helps explain why a medicine that works well for one person may not provide the same benefit to another. Researchers are exploring whether better understanding of individual inflammatory patterns could help clinicians select treatments more precisely.()

Researchers are investigating several approaches to address treatment resistance in rheumatoid arthritis. Many are still experimental, and further studies are needed to establish their effectiveness and safety.

Chimeric antigen receptor (CAR) T-cell therapy involves modifying immune cells so they can recognise and target selected cells. In autoimmune disease research, one proposed application is to target abnormal or autoreactive B cells involved in harmful immune responses.

The approach is attracting interest because it may offer a way to reset parts of the immune system rather than simply suppressing one inflammatory signal. However, CAR T-cell therapy remains an investigational strategy for rheumatoid arthritis and is not a standard treatment for routine care.

Nanocarriers are very small delivery systems being studied to transport medicines to particular tissues or cells. The review discusses engineered nanocarriers designed to influence drug-efflux pumps in joint tissue.

The goal is to improve the amount of therapeutic medicine retained where it is needed. This remains a research direction, not an established clinical solution for methotrexate resistance.

Because several inflammatory pathways may contribute to rheumatoid arthritis, researchers are exploring treatments that inhibit more than one cytokine pathway. The aim is to reduce the possibility that inflammation will continue through an alternative signalling route.

The potential benefit must be balanced against safety. Blocking multiple immune pathways could also affect the body's ability to respond to infections, making careful clinical testing essential.

Regulatory T cells, often called Tregs, help prevent the immune system from attacking the body's own tissues. Low-dose interleukin-2 (IL-2) is being investigated as a way to support the expansion or activity of these regulatory cells.

The strategy aims to restore some balance in immune regulation. Its role in difficult-to-treat rheumatoid arthritis remains under investigation.

The vagus nerve is involved in communication between the brain and several organs. Researchers are studying whether stimulating this nerve can influence inflammatory responses through neural and immune signalling pathways.

Implantable or other forms of neurostimulation may offer a different way of influencing inflammation. However, further clinical evidence is needed before such approaches can be considered routine rheumatoid arthritis treatment.

Multi-omics research combines information from areas such as genomics, gene expression, proteins and metabolism. By examining several biological layers together, researchers hope to identify patterns linked to treatment response or resistance.

In the future, this information may help clinicians understand why a particular medicine is not working and identify alternative treatment targets. For now, multi-omics-guided treatment selection is an evolving research area rather than a standard approach available to every patient.

Persistent symptoms deserve reassessment, but treatment resistance should not be assumed without examining other possible explanations. A rheumatologist may consider: A review of Phase 4 clinical trial evidence published in 2026 also highlights the continued This reinforces that managing difficult disease is not only about discovering new medicines; it also involves making the best use of existing treatment options.()

Persistent inflammation can contribute to progressive joint damage and reduced physical function. Recognising inadequate treatment response early gives clinicians an opportunity to reassess the diagnosis, identify barriers to treatment and consider other disease-modifying options.

There is no single treatment strategy that works for everyone with rheumatoid arthritis. The choice of therapy depends on disease activity, previous treatment response, other health conditions, potential side effects and patient preferences.

People should not stop methotrexate or biologic medicines, change doses or combine treatments without speaking to their treating clinician. These medicines require appropriate monitoring, and changes to treatment should be guided by a rheumatologist.()

Persistent symptoms do not always mean that a rheumatoid arthritis medicine has stopped working. Doctors may need to check for active inflammation, treatment adherence, side effects and other causes of pain before changing treatment. Although new approaches are being studied, careful clinical reassessment remains essential in difficult-to-treat rheumatoid arthritis.